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Filaggrin Null Alleles Are Not Associated with
Psoriasis
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Psoriasis is a common skin disease with an etiology consistent with a multifactorial trait. Several psoriasis
susceptibility loci are known, a number of which are also implicated in a predisposition to atopic dermatitis
(AD), including the epidermal differentiation complex on chromosome 1q21. It has recently been shown in
several replicate studies that prevalent null alleles for the filaggrin gene (FLG) on 1q21 are an important genetic
factor in AD. Here, we examined the role of these FLG variants in psoriasis using case:control association studies
comparing Irish and UK psoriasis cohorts (combined n¼ 691) to ethnically matched populations (combined
n¼ 2117). No association was present for the two common European FLG mutations R501X and 2282del4
(combined w2 P¼ 0.989). In addition, the 30 end of the FLG open-reading frame was sequenced in a number of
patients with differing types of psoriasis (plaque, guttate, palmoplantar, and late-onset), which excluded the
possibility of a gain-of-function frameshift mutation such as those found in loricrin or certain keratin genes.
These data suggest that FLG mutations are unlikely to be involved in genetic susceptibility to psoriasis and
implies that there may be within-locus heterogeneity in chromosomal regions involved in both AD and
psoriasis.
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INTRODUCTION
Psoriasis is a chronic inflammatory skin condition affecting
2–3% of many human population groups and is therefore a
considerable cause of morbidity worldwide (Griffiths et al.,
2004; Smith and Barker, 2006). The disease presents as a
variety of distinguishable subtypes and appears to be a classic
multifactorial disorder where genetic predisposition factors
combine with environmental stimuli to produce the disease.
Stable psoriasis is a heterogeneous disorder with a number of
distinct clinical phenotypes suggesting possible different
genetic backgrounds. These include chronic plaque psoriasis,
guttate psoriasis, and palmoplantar pustular psoriasis (palmo-
plantar pustulosis). Two further groupings of chronic plaque
psoriasis have been recognized, early-onset psoriasis (Type 1
psoriasis) with onset generally before the age of 40 years, and
late-onset psoriasis (Type 2 psoriasis) with onset after the age
of 50 years (Griffiths et al., 2004). Late-onset and palmo-
plantar pustular variants have been shown to be genetically
distinct from classic forms of psoriasis and perhaps should not
be considered as psoriasis per se (Asumalahti et al., 2003;
Allen et al., 2005). A number of susceptibility loci have been
mapped by linkage analysis in large families or by genome-
wide transmission studies, including genetic linkage in
families, transmission disequilibrium testing, and sibling-pair
analysis. The predominant locus for psoriasis vulgaris is
PSORS1, which lies in the region of the major histocompat-
ibility complex on chromosome 6p21.3, where about half of
all psoriatic patients carry the HLA-Cw6 allele (Trembath
et al., 1997). Recent data suggest that the Cw6 allele may in
fact be the causative variant; however, this awaits indepen-
dent confirmation (Nair et al., 2006). A number of other loci
have been mapped for psoriasis, as reviewed recently
(Bowcock and Cookson, 2004; Capon et al., 2004; Bowcock
ORIGINAL ARTICLE
1878 Journal of Investigative Dermatology (2007), Volume 127 & 2007 The Society for Investigative Dermatology
Received 2 November 2006; revised 12 December 2006; accepted 14
January 2007; published online 5 April 2007
1Epithelial Genetics Group, Human Genetics Unit, Division of Pathology and
Neuroscience, University of Dundee, Ninewells Hospital and Medical
School, Dundee, UK; 2Population Pharmacogenetics Group, Biomedical
Research Centre, University of Dundee, Ninewells Hospital and Medical
School, Dundee, UK; 3King’s College London, St John’s Institute of
Dermatology, St Thomas’s Hospital, London, UK; 4King’s College,
Department of Medical and Molecular Genetics, London, UK;
5Dermatopharmacology Unit, The Dermatology Center, University of
Manchester, Hope Hospital, Manchester, UK; 6Department of Dermatology,
Western Infirmary, Glasgow, UK; 7Department of Clinical Medicine, Institute
of Molecular Medicine Trinity College Dublin, Dublin, Ireland; 8Genetic
Repository in Ireland for Psoriasis and Psoriatic Arthritis (GRIPsA), St Vincent’s
University Hospital, Elm Park, Dublin, Ireland; 9Department of Dermatology,
St Vincent’s University Hospital, Elm Park, Dublin, Ireland; 10Department of
Rheumatology, St Vincent’s University Hospital, Elm Park, Dublin, Ireland;
11Department of Rheumatology, Adelaide and Meath Hospital incorporating
the National Children’s Hospital, Tallaght, Dublin, Ireland and 12Department
of Paediatric Dermatology, Our Lady’s Children’s Hospital, Crumlin, Dublin,
Ireland
Correspondence: Dr Irwin McLean, Human Genetics Unit, University of
Dundee, Dundee DD1 9SY, UK. E-mail: w.h.i.mclean@dundee.ac.uk
Abbreviations: AD, atopic dermatitis; EDC, epidermal differentiation complex
and Krueger, 2005; Kere, 2005) and interestingly, a number
of the known susceptibility loci for psoriasis are also shared
with susceptibility for atopic dermatitis (AD), another
common inflammatory skin condition that is inherited as a
multifactorial complex trait (Bowcock and Cookson, 2004).
AD is more common than psoriasis, affecting up to 20% of
children in the developed world. It is also associated with the
progressive development of a range of other allergic
conditions that make up the ‘‘atopic march’’ which include
food allergy, asthma, rhinitis, and others (Spergel and Paller,
2003). The apparent colocalization of these two inflamma-
tory skin diseases suggests two possible pathomechanistic
hypotheses. Firstly, variations within a single gene located in
these shared loci might predispose to both of these
inflammatory skin diseases. Included in this hypothesis is
the possibility that distinct classes of mutations in the same
gene, for example, nonsense or missense mutations, are
involved AD or psoriasis, respectively. The second, alter-
native, hypothesis is that some of these loci may be gene
clusters where polymorphisms in two or more physically
close and genetically similar genes, encoding functionally
related but nevertheless distinct molecules, might give rise to
either psoriasis or AD.
One such shared locus is the epidermal differentiation
complex (EDC) on chromosome 1q21.3, a cluster of many
dozens of genes encoding molecules found in the uppermost
layers of the differentiating epidermis (Bowcock and Cook-
son, 2004). The EDC region was identified as a susceptibility
locus for psoriasis by analysis of Italian kindreds (Capon
et al., 1999, 2001) and was subsequently shown to be a locus
for AD (Cookson et al., 2001). Recently, we have shown that
loss-of-function alleles of FLG, the gene encoding filaggrin,
which is located in the EDC, cause the common monogenic
skin disorder ichthyosis vulgaris (Sandilands et al., 2006;
Smith et al., 2006). We went on to show that these same
common mutations, carried by B9% of white European
populations, also determine major susceptibility to early-
onset, persistent, moderate-to-severe AD and eczema-asso-
ciated asthma (Palmer et al., 2006). This association has
already been replicated several times in a range of European
populations (Marenholz et al., 2006; Ruether et al., 2006;
Weidinger et al., 2006; Barker et al., 2007; Stemmler et al.,
2007) and so represents a highly robust association of an EDC
gene in AD and the secondary allergic diseases that make up
the atopic march (Spergel and Paller, 2003).
Intriguingly, there are reports in the literature of changes in
the expression pattern of filaggrin in psoriatic epidermis,
compared to both non-lesional skin and normal controls.
Specifically, filaggrin expression is lost from the granular
layer in psoriatic lesions although it is present in non-lesional
epidermis (Watanabe et al., 1991). However, there are also
changes in the expression of other EDC-encoded proteins
closely related to filaggrin, such as hornerin, which is
upregulated in psoriatic lesions (Takaishi et al., 2005) or
trichohyalin, which is redistributed in psoriatic plaques
(Ishida-Yamamoto et al., 1997). Thus, it remains to be seen
if the alterations in filaggrin expression in psoriasis are
primary or secondary events in the pathogenesis of the
disease. Here, we address the question as to whether or not
the same filaggrin null variants found in up to half of AD
individuals are also the 1q21 genetic predisposing factor for
psoriasis.
RESULTS AND DISCUSSION
Two FLG mutations, R501X and 2282del4, are prevalent in
the white European population (Palmer et al., 2006). Both
variants lead to premature termination of profilaggrin
translation within the first filaggrin repeat domain and
therefore are functional null alleles for filaggrin, the end
product of the FLG gene (Smith et al., 2006). A total of 271
Irish cases of psoriasis vulgaris and 654 unselected Irish
controls were genotyped for R501X and 2282del4 using
established methods (Palmer et al., 2006). Comparison of the
allele frequencies between the psoriasis cohort with the Irish
population controls gave a Pearson w2 value of P¼0.075 for
the R501X variant and P¼ 0.932 for 2282del4 allele (Table 1).
Thus, there appeared to be a weak association of the R501X
variant but did not reach significance. Combining both null
allele genotypes resulted in w2 P¼0.169 (Table 1) and
therefore there was no significant association of these FLG
null alleles with psoriasis in the Irish population.
By the same methods, 420 UK cases of psoriasis were
compared with 1463 ethnically matched population controls.
The R501X allele again gave a weak association that failed to
reach significance, w2 P¼ 0.075, whereas the 2282del4 allele
showed no significant association (P¼0.366). Combining the
genotype data for the two null alleles gave no significant
association overall (P¼0.419; Table 2).
Combining the Irish and UK psoriasis cohorts (n¼691)
and comparing these with the combined Irish/UK population
controls (n¼ 2117) gave no significant association for either
R501X (P¼0.515), 2282del4 (P¼0.457), or the combined
genotype (P¼0.989; see Table 3). Another way of consider-
ing these data is that the combined allele frequency was
essentially identical in the psoriasis cases (0.041, 95%
confidence interval 0.031–0.052) and the combined controls
(0.041, 95% confidence interval 0.035–0.047); the larger
number of controls (n¼ 2117) giving slightly tighter con-
fidence intervals compared to the patient cohort (n¼691).
Table 1. Irish psoriasis case:control association study
R501X 2282del4 Combined genotype
Population Psoriasis Population Psoriasis Population Psoriasis
AA 634 256 633 262 613 247
Aa 20 15 21 9 41 24
aa 0 0 0 0 0 0
654 271 654 271 654 271
P=0.075 P=0.932 P=0.169
AA, homozygous wild type for FLG null variant; Aa, heterozygous for
either of the common FLG null alleles R501X or 2282del4; aa,
homozygous or compound heterozygous for FLG null alleles R501X or
2282del4.
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Thus, the very weak and opposing associations observed in
the individual Irish and UK cohorts for R501X completely
disappear in a larger case:control association study, and these
results strongly suggest that filaggrin null alleles do not
account for the 1q21 linkage observed in psoriasis. As it has
been shown that the late-onset and palmoplantar pustular
forms of psoriasis lack the strong HLA-Cw6 association seen
in psoriasis vulgaris and guttate psoriasis (Asumalahti et al.,
2003; Allen et al., 2005), we extracted the data for the former
subtypes from the patient cohorts and considered these
separately. This showed that the combined FLG null allele
frequency did not vary significantly from the population
controls for either palmoplantar pustular (n¼ 78; P¼0.566)
or late-onset psoriasis (n¼ 93; P¼ 0.329). Therefore, neither
of the two apparently genetically distinct psoriasis variants
shows association with the two common filaggrin null
variants.
Many of the genes in the EDC, including those encoding
filaggrin and loricrin, consist of highly repetitive sequences
both at the DNA and protein level. A consequence of this
type of repetitive sequence is that frameshift mutations may
not lead to premature termination codon mutations for a
considerable distance following the frameshift. Depending on
the precise sequence involved, this can lead to the expression
of long foreign peptide fused to the N-terminus of the protein,
which exerts a powerful dominant-negative effect. Such
delayed termination codon mutations in the loricrin gene are
the cause of the Camisa type mutilating keratoderma
(Maestrini et al., 1996) and similar defects in the final exon
of the keratin 1 gene, which is structurally similar to loricrin,
filaggrin, and other EDC genes, leads to a form of ichthyosis
hystrix (Sprecher et al., 2001). To exclude the possibility that
this class of mutation might lead to psoriasis susceptibility,
we undertook sequencing of the 30end of the FLG exon 3, in
four unrelated patients with each of the following subtypes:
early-onset plaque, palmoplantar pustular, guttate, and late-
onset plaque psoriasis (i.e., 16 patients in total). Specifically,
the region of FLG exon 3 encoding filaggrin repeats 9, 10 and
the partial repeat 11, was amplified using repeat-specific
primers in three overlapping PCR fragments and fully
sequenced using internal primers ending on unique non-
polymorphic bases. No sequence changes were detected in
these patients and so this type of C-terminal gain of function
mutation was excluded.
Filaggrin is a highly abundant protein in the outermost
layers of the epidermis. The keratohyalin granules which give
the granular cells their name are mainly composed of the
4400 kDa profilaggrin, which upon terminal differentiation
is proteolytically cleaved into 10 or more copies of the
37 kDa filaggrin protein (Presland and Dale, 2000; Candi
et al., 2005). The liberated filaggrin binds to and aggregates
the keratin cytoskeleton leading to keratinocyte compaction
and formation of the stratum corneum. Patients homozygous
for the R501X or 2282del4 mutations in FLG completely lack
keratohyalin granules in their skin and have severe ichthyosis
vulgaris and a high risk of atopic disease (Palmer et al., 2006).
Heterozygotes may show subtle signs of ichthyosis vulgaris
and have a high risk of developing AD. It has also been
suggested that filaggrin is further broken down in the stratum
corneum into hygroscopic amino acids and derivatives
thereof that may act as a natural moisturizing substance
(Rawlings and Harding, 2004). Thus, complete loss of
filaggrin or haploinsufficiency for the protein is consistent
with the xerotic skin and impaired barrier function observed
in ichthyosis vulgaris and AD. The inflammation of the skin
seen in filaggrin mutation carriers is thought to be a
secondary phenomenon following increased transepidermal
antigen/allergen/irritant transfer through the defective skin
barrier (Hudson, 2006). The coincident genetic linkage of
psoriasis to 1q21 suggests that an analogous mechanism
might also be a factor in this inflammatory skin disease.
Here, we have shown that although the EDC on 1q21.3,
containing FLG, is a recognized psoriasis susceptibility locus,
FLG null alleles are not predisposing factors in psoriasis.
Furthermore, we have excluded mutations in the 30 end of
Table 2. UK psoriasis case:control association study
R501X 2282del4 Combined genotype
Population Psoriasis Population Psoriasis Population Psoriasis
AA 1381 406 1414 402 1334 388
Aa 79 13 49 18 124 31
aa 3 1 0 0 5 1
1463 420 1463 420 1463 420
P=0.075 P=0.366 P=0.419
AA, homozygous wild type for FLG null variant; Aa, heterozygous for
either of the common FLG null alleles R501X or 2282del4; aa,
homozygous or compound heterozygous for FLG null alleles R501X or
2282del4.
For the combined genotype data, note that compound heterozygotes are
counted as ‘aa’. For example, in the population cohort, the total is five
(three R501X homozygotes, plus two R501X/2282del4 compound
heterozygotes). For this reason, the figures in this table do not appear to
add up at first glance.
Table 3. Combined UK/Irish psoriasis case:control
association study
R501X 2282del4 Combined genotype
Population Psoriasis Population Psoriasis Population Psoriasis
AA 2015 662 2047 664 1947 635
Aa 99 28 70 27 165 55
aa 3 1 0 0 5 1
2117 691 2117 691 2117 691
P=0.515 P=0.457 P=0.989
AA, homozygous wild type for FLG null variant; Aa, heterozygous for
either of the common FLG null alleles R501X or 2282del4; aa,
homozygous or compound heterozygous for FLG null alleles R501X or
2282del4.
For the combined genotype data, note that compound heterozygotes are
counted as ‘aa’. For example, in the population cohort, the total is five
(three R501X homozygotes, plus two R501X/2282del4 compound
heterozygotes). For this reason, the figures in this table do not appear to
add up at first glance.
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filaggrin gene in 16 patients with four specific subtypes of
psoriasis. Therefore, it appears that the EDC psoriasis gene,
PSORS4 (Capon et al., 1999), is not FLG. Our data are
consistent with the high-resolution linkage mapping of this
locus using Italian families, which suggested that the
causative variant for psoriasis is in the vicinity of the loricrin
gene (Capon et al., 2001), although the coding regions of this
gene do not appear to harbor mutations or variants that fully
co-segregate with psoriasis (Giardina et al., 2004). Poly-
morphisms affecting the loricrin promoter may exist but are
more difficult to prove as causative at the functional level
compared to null mutations. The fact that FLG can be
excluded as an EDC gene for psoriasis, although it is clearly
very important in AD suggests that, in the 1q21 locus at least,
the shared genetic susceptibility observed for these inflam-
matory skin conditions may be due to the clustering of genes
with similar but non-identical functions rather than distinct
clinical conditions arising from the same causative poly-
morphisms. It will be of interest to see if this trend also holds
true for the other shared eczema/psoriasis loci on 3q21,
17p25, and 20p once the causative genes are determined. As
filaggrin is a key player in epidermal barrier formation and
hydration, will the psoriasis gene on 1q21 also be a barrier
protein or will it have an immune regulatory function, as
suggested for members of the S100 protein family nearby?
Further fine mapping and molecular genetic characterization
of genes within this locus should shed light on this question in
the near future.
MATERIALS AND METHODS
Study populations
All DNA samples were collected with institutional research ethics
committee approval (St James Hospital and Adelaide and Meath
Hospital Ethics Committee, St Vincents’s University Hospital Ethics
Committee, and King’s College London Ethics Committee) and
informed consent that complies with the Declaration of Helsinki
Principles. All subjects were of white Irish or British ancestry.
Filaggrin genotyping
Genotyping for R501X was performed using a TAQMAN-based
allelic discrimination assay (Applied Biosystems, Foster City, CA).
Standard procedures were used based on Applied Biosystems
reagents and 10 ml reaction volumes. Allelic discrimination was
assessed using an Applied Biosystems 7700 sequence detection
system. Probes and primers were as described previously (Palmer
et al., 2006). Mutation 2282del4 was genotyped by sizing of a
fluorescent-labelled PCR fragment on an Applied Biosystems 3100
or 3730 DNA sequencer as described previously (Palmer et al.,
2006). The region of FLG exon 3 encoding filaggrin repeats 9, 10 and
the partial repeat 11 was amplified using repeat-specific primers in
three overlapping PCR fragments and fully sequenced using internal
primers ending on unique non-polymorphic bases (A. Sandilands
and W.H.I. McLean, paper in preparation).
Statistical analysis
Power calculations were carried out assuming a disease prevalence
for psoriasis of 2% and a gene dose multiplicative model (which is
observed for AD). These calculations showed that the study had 89%
power to detect a genotype relative risk of 2 at an alpha of 0.05, or
80% power to detect a genotype relative risk of 1.87 at an alpha of
0.05. That is, the study had ample power to detect the types of
genetic associations being sought here. All statistical analyses in the
association studies were performed using SPSS for Windows, v.11.5
or Instat 3 for Macintosh (Graphpad Software Inc., San Diego, CA).
Allele frequencies were compared using Pearson w2 tests of the three
genotype frequencies (AA, Aa, aa). All variants were in Hard-
y–Weinberg equilibrium. Note that when combining the two null-
genotypes, ‘‘AA’’ refers to an individual who carries neither FLG
mutation; ‘‘Aa’’ refers to an individual who is heterozygous for either
R501X or 2282del4; and ‘‘aa’’ refers to individuals homozygous for
either R501X or 2282del4 or, compound heterozygous for R501X/
2282del4.
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